Search

Search Constraints

You searched for: Author/Creator Michaelsen, Signe Regner

Search Results

1. Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. Issue 8 (26th May 2016)

2. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma. Issue 5 (18th March 2020)

3. BIOM-51. ELUCIDATION OF THE TRANSCRIPTOMIC CONSEQUENCES OF KLF4 AND TRAF7 MUTATIONS IN SECRETORY MENINGIOMAS. (14th November 2022)

4. Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. (7th February 2018)

5. Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. (2nd April 2016)

7. PATH-01. IDENTIFICATION OF PROGNOSTIC VARIABLES BASED ON MOLECULAR PROFILING OF LONG-TERM AND SHORT-TERM SURVIVING GLIOBLASTOMA PATIENTS. (6th November 2017)

8. Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors. Issue 7 (29th December 2021)

9. Targeting glioma stem‐like cell survival and chemoresistance through inhibition of lysine‐specific histone demethylase KDM2B. Issue 3 (12th February 2018)